Bedford, Mass. — November 4, 2025 — Leads & Copy —
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced that its SOL-R registrational trial of AXPAXLI™ in wet age-related macular degeneration (AMD) has achieved its randomization target of 555 subjects. Topline data is expected in the first half of 2027.
The company will continue to allow randomization of previously enrolled subjects currently in the loading phase of the trial to maintain its commitment to both patients and investigators. SOL-1 and SOL-R are designed to complement each other.
According to Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer of Ocular Therapeutix, the SOL program underscores the strong demand among retina specialists and patients for more durable therapies like AXPAXLI that can potentially deliver better long-term outcomes while reducing the treatment burden.
SOL-R is a Phase 3, multi-center, double-masked, randomized (2:2:1) trial evaluating AXPAXLI dosed every 6 months versus aflibercept (2 mg) dosed every 8 weeks in treatment-naïve wet AMD patients. The primary endpoint is to demonstrate non-inferiority in mean change in best corrected visual acuity (BCVA) from baseline at Week 56.
Contact: Bill Slattery, Vice President, Investor Relations, bslattery@ocutx.com
Source: Ocular Therapeutix, Inc.
